Surgery Partners' Growth Prospects Bolster Buy Rating
Ascend Plastic Surgery Partners Expands Elite Network With Inclusion of Tallahassee Plastic Surgery Clinic
TALLAHASSEE, FL / ACCESSWIRE / May 14, 2024 / Ascend Plastic Surgery Partners (Ascend), a leading network of top-tier plastic surgeons and aesthetic centers, proudly announces the addition of Tallahas
Surgery Partners (SGRY) Outperforms With Strong Q1 and Strategic Focus: A Buy Rating Maintained
Surgery Partners Is Maintained at Buy by Citigroup
Surgery Partners Is Maintained at Buy by Citigroup
Surgery Partners Price Target Cut to $38.00/Share From $42.00 by Citigroup
Surgery Partners Price Target Cut to $38.00/Share From $42.00 by Citigroup
Citigroup Maintains Buy on Surgery Partners, Lowers Price Target to $38
Citigroup analyst Jason Cassorla maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $42 to $38.
Surgery Partners Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 40.14% Citigroup $42 → $38 Maintains Buy 05/01/2024 84.4% Benchmark → $50 Reiterates Buy → Buy
Surgery Partners, Inc. (NASDAQ:SGRY) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Surgery Partners(SGRY.US) Q1 2024 Earnings Conference
The following is a summary of the Surgery Partners, Inc. (SGRY) Q1 2024 Earnings Call Transcript:Financial Performance:Surgery Partners Q1 net revenue was approximately $717 million, a 7.7% growth fro
Surgery Partners: Strong Fundamentals and Market Trends Justify Buy Rating Amidst Favorable Growth Projections
Surgery Partners First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Repare Therapeutics (RPTX) and Penumbra (PEN)
Surgery Partners (SGRY) Gets a Buy From RBC Capital
Barclays Sticks to Its Hold Rating for Surgery Partners (SGRY)
Surgery Partners Inc (SGRY) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and ...
Express News | Surgery Partners Inc : Leerink Partners Cuts Target Price to $41 From $47
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Surgery Partners (SGRY)
Surgery Partners | 10-Q: Quarterly report
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday's session following weaker-than-expected quarterly results.Beyond posted adjusted loss of $1.22 per share, versus estimates for a loss of
Express News | Surgery Partners Shares Are Trading Higher Following Strong Q1 Earnings
No Data